Patients with new or recurrent stroke

CONSIDER ELIGIBILITY & SCREEN
(Screen from Day 0; confirm eligibility from Day 5 –42)

Day 0

Day 5

Eligible

Ineligible*

Ineligible

Return Screening Form

Discuss trial participation ASAP and provide Information Sheet

Weekly screening up to end of recruitment

Decline

Obtain written informed consent

Eligible

Consider Carer participation and consent if appropriate

Complete baseline assessments and randomise

First 2 doses administered as inpatient at ½ strength in hospital

Drug therapy continues in hospital or in community setting for up to 6 weeks, maximum of twice per day

Follow up in patient’s homes
At 8 weeks (primary end point), 6 months and 12 months post randomisation

≥24 hours

Up to day 42

*Inclusion criteria 6, 8 and other co morbidities should be monitored up to 42 days post stroke as patients initially not meeting the eligibility criteria may improve within the 42 days post stroke.